Keyphrases
After Surgery
11%
Age Groups
5%
Aggregate Data
8%
Androgen Deprivation Therapy
23%
ARAMIS
8%
Bladder Cancer
5%
Breast Cancer
8%
Cancer Mortality
7%
Cancer Treatment
5%
Cancer-related
6%
Castration-resistant Prostate Cancer
13%
Clinical Outcomes
5%
Clinically Significant Prostate Cancer
5%
Comorbidity
6%
Confidence Interval
22%
Darolutamide
12%
Drug Use
5%
Economic Factors
5%
Elderly Patients
8%
EPIC-26
10%
Europe
10%
European Randomized Study of Screening for Prostate Cancer
10%
Euthyroid
12%
Expanded Prostate Cancer Index Composite
8%
Finland
28%
Functional Outcome
7%
Geoeconomics
5%
Hazard Ratio
11%
High-grade Prostate Cancer
14%
Hypothyroid
6%
Hypothyroidism
13%
International Survey
8%
Laparoscopic Radical Prostatectomy
12%
Levothyroxine
5%
Long Non-coding RNA (LncRNA)
8%
Lower Urinary Tract Symptoms
8%
Lymph Node Metastasis
6%
Lynch Syndrome
8%
Magnetic Resonance Imaging
10%
Metastasis
5%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
14%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
8%
Multivariable
5%
Non-associated
5%
Non-muscle Invasive Bladder Cancer (NMIBC)
5%
Nonmetastatic Prostate Cancer
5%
Oncological Outcomes
7%
Overall Survival
18%
Patients with Prostate Cancer
12%
Placebo
5%
Population-based Cohort Study
5%
Primary Prostate Cancer
5%
Prognostic Factors
9%
Prostate
14%
Prostate Cancer
75%
Prostate Cancer Patients
14%
Prostate Cancer Risk
30%
Prostate Cancer Screening
27%
Prostate Radiotherapy
10%
Prostate-specific Antigen
13%
Prostate-specific Antigen Testing
7%
Prostatectomy
8%
Quality of Life
7%
Radical Prostatectomy
12%
Random Forest Algorithm
5%
Randomized Controlled Trial
9%
Randomized Trial
8%
Reoperation
5%
Risk Factors
8%
Risk of Death
8%
Robot-assisted
8%
Sensitivity Analysis
5%
Statin Use
12%
Statins
8%
Tampere
5%
Testosterone
8%
Three-dimensional (3D)
12%
Thyroid Hormones
8%
Tolerability
9%
Total Prostate-specific Antigen
8%
Treatment-related Adverse Events
5%
University Hospital
7%
Urinary Incontinence
5%
Visual Analog Scale
5%
Well-being
5%
Medicine and Dentistry
Androgen
5%
Androgen Deprivation Therapy
16%
Androgen Receptor
5%
Arm
9%
Biopsy Technique
5%
Breast Cancer
5%
Cancer Cell
7%
Cancer Mortality
19%
Cancer Screening
13%
Cancer Therapy
7%
Castration Resistant Prostate Cancer
8%
Clear Cell Renal Cell Carcinoma
12%
Cohort Analysis
6%
Colorectal Carcinoma
5%
Comorbidity
6%
Continence
9%
Cystectomy
8%
Diseases
7%
Elderly Patient
8%
Gene Expression
8%
Hazard Ratio
6%
Hereditary Nonpolyposis Colorectal Cancer
8%
Hernioplasty
5%
Hypothyroidism
13%
Levothyroxine
5%
Liotrix
12%
Lymph Node Metastasis
6%
Magnetic Resonance Imaging
12%
Malignant Neoplasm
8%
Medical Record
5%
Metastatic Carcinoma
5%
Neoplasm
8%
Overall Survival
9%
Prognostic Factor
8%
Prostate Cancer
100%
Prostate Specific Antigen
15%
Prostatectomy
27%
Quality of Life
7%
Randomized Controlled Trial
16%
Recurrent Disease
6%
Reoperation
5%
Robot-Assisted Prostatectomy
9%
Screening of Prostate Cancer
9%
Thyroid Gland
16%
Thyroid Hormone
8%
Urinary System
7%
Visual Analog Scale
5%